Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for dexamfetamine, the scientific conclusions are as follows:

The literature review provided further evidence of a link between dexamfetamine administration and "Increased cortisol level". The observed effects appear to be common to the amphetamine class of drugs, however the mechanism involved isn't currently fully understood and any potential clinical manifestations are unknown. Nevertheless, the impact of this rise in laboratory tests is clear and such information should be present in the PI as it is already for other amphetamines. Cortisol level determination is an important diagnostic tool for several disorders. To know that a patient is taking dexamphetamine is important to accurately interpret the results of cortisol levels, in the context of the laboratorial evaluation of endocrine disorders. Additional information on the PIL aims to further inform patient of the impact on laboratory analysis.

Based on this data the Lead Member State concluded that the product information of products containing dexamfetamine should be amended accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for dexamfetamine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing dexamfetamine is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing dexamfetamine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **<u>underlined and in bold</u>**, deleted text ~~strike through~~)

Summary of Product Characteristics

Section 4.5

<u>Drug/laboratory test interactions</u>

<u>Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.</u>

Remove sentence (or similar wording) if present in SmPC: ~~Athletes must be aware that this medicinal product may cause a positive reaction to 'anti-doping' tests.~~

Package Leaflet

- Section 2 What you need to know before you take

<u>Drug/laboratory test interactions</u>

<u>This medicine may interfere with your laboratory test results.</u>

Remove sentence (or similar wording) if present in PIL: ~~Athletes must be aware that this medicinal product may cause a positive reaction to 'anti-doping' tests.~~

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	April 2022 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	28 May 2022
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	27 July 2022